WO1996005836A3 - Methods of treating cold symptoms using pentoxifylline - Google Patents

Methods of treating cold symptoms using pentoxifylline Download PDF

Info

Publication number
WO1996005836A3
WO1996005836A3 PCT/US1995/010840 US9510840W WO9605836A3 WO 1996005836 A3 WO1996005836 A3 WO 1996005836A3 US 9510840 W US9510840 W US 9510840W WO 9605836 A3 WO9605836 A3 WO 9605836A3
Authority
WO
WIPO (PCT)
Prior art keywords
pentoxifylline
subject
methods
analog
effective amount
Prior art date
Application number
PCT/US1995/010840
Other languages
French (fr)
Other versions
WO1996005836A2 (en
Inventor
Ronald B Turner
Original Assignee
Univ South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Carolina filed Critical Univ South Carolina
Priority to AU35397/95A priority Critical patent/AU3539795A/en
Publication of WO1996005836A2 publication Critical patent/WO1996005836A2/en
Publication of WO1996005836A3 publication Critical patent/WO1996005836A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Abstract

The invention provides a method of alleviating a symptom of an upper respiratory viral infection in a subject, comprising administering to the subject an effective amount of pentoxifylline or an analog thereof. The invention also provides a method of inhibiting interleukin-8 elaboration in a subject comprising administering to the subject an effective amount of pentoxifylline or an analog thereof. A pharmaceutical composition for alleviating a symptom of an upper respiratory viral infection is also provided, comprising an effective amount of pentoxifylline or an analog thereof in a pharmaceutically acceptable nasal spray carrier.
PCT/US1995/010840 1994-08-25 1995-08-25 Methods of treating cold symptoms using pentoxifylline WO1996005836A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35397/95A AU3539795A (en) 1994-08-25 1995-08-25 Methods of treating cold symptoms using pentoxifylline

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29648794A 1994-08-25 1994-08-25
US08/296,487 1994-08-25

Publications (2)

Publication Number Publication Date
WO1996005836A2 WO1996005836A2 (en) 1996-02-29
WO1996005836A3 true WO1996005836A3 (en) 1996-04-18

Family

ID=23142202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/010840 WO1996005836A2 (en) 1994-08-25 1995-08-25 Methods of treating cold symptoms using pentoxifylline

Country Status (2)

Country Link
AU (1) AU3539795A (en)
WO (1) WO1996005836A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
PL365886A1 (en) * 2000-07-18 2005-01-10 Smithkline Beecham Corporation Use of il-8 receptor antagonists in the treatment of virus infections
WO2009108375A1 (en) 2008-02-29 2009-09-03 Concert Pharmaceuticals, Inc Substituted xanthine derivatives
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2473052A4 (en) 2009-09-02 2013-03-20 Concert Pharmaceuticals Inc Substituted xanthine derivatives
GB2475359A (en) * 2009-11-11 2011-05-18 Biocopea Ltd A compound for use in treating a fulminant respiratory disorder
US20130324564A1 (en) 2010-09-01 2013-12-05 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)-dione
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
KR20150002779A (en) 2012-04-13 2015-01-07 콘서트 파마슈티컬즈, 인크. Substituted xanthine derivatives
WO2013159006A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279079A2 (en) * 1986-12-31 1988-08-24 Hoechst-Roussel Pharmaceuticals Incorporated Purine derivatives as interleukin-1 inhibitors
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US5196430A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5196429A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
EP0609606A1 (en) * 1992-10-01 1994-08-10 The Wellcome Foundation Limited Tucaresol as an immunopotentiatory agent

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279079A2 (en) * 1986-12-31 1988-08-24 Hoechst-Roussel Pharmaceuticals Incorporated Purine derivatives as interleukin-1 inhibitors
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US5196430A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5196429A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
EP0609606A1 (en) * 1992-10-01 1994-08-10 The Wellcome Foundation Limited Tucaresol as an immunopotentiatory agent
EP0678298A2 (en) * 1992-10-01 1995-10-25 The Wellcome Foundation Limited Use of 4-(2-formyl-3-hydroxyphenoxymethyl)benzoic acid as immopotentiatory agent

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A.M.VAN FURTH: "In Vitro Effect of Dexamethasone, Pentoxifylline..", PEDIATRIC RESEARCH, vol. 35, no. 6, pages 725 - 728 *
G.C.RICE ET AL.: "CT-1501R SELECTIVELY INHIBITS INDUCED INFLAMMATORY MONOKINES IN HUMAN WHOLE BLOOD EX VIVO", SHOCK, vol. 1, no. 4, pages 254 - 266 *
K.D.YANG ET AL.: "Neuroblastoma Cell-Mediated Leukocyte Chemotaxis: Lineage-Specific Differentiation of Interleukin-8 Expression", EXPERIMENTAL CELL RESEARCH, vol. 211, no. 1, pages 1 - 5 *
P.NEUNER ET AL.: "Pentoxifylline in vivo down-regulates the release of IL-1beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells", IMMUNOLOGY, vol. 83, no. 2, pages 262 - 267 *
R.B.TURNER, ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 34, pages 65 *
S.MIKI ET AL.: "Effects of propentofylline on the production of IFN-.gamma. and IL-8 by peripheral blood mononuclear cells in vitro", DIALOG INFORMATION SERVICES, FILE 399: CA SEARCH, ABSTRACT 118: 32686Z *

Also Published As

Publication number Publication date
AU3539795A (en) 1996-03-14
WO1996005836A2 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
EP0911033A3 (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
EP0682526A4 (en) PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS.
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
UA41906C2 (en) Method for treating neurological disorders due to trauma
CA2146954A1 (en) Breath activated nicotine inhalers
CA2184077A1 (en) Nasal and ocular administration of ketamine to manage pain and for detoxification
EP1019072A4 (en) Method for assisting in differential diagnosis and treatment of autistic syndromes
CA2155200A1 (en) Use of topical anesthetics for the treatment of eosinophil-associated diseases
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
EP0352025A3 (en) Use of nalmefene in the treatment of allergic rhinitis
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO1996005836A3 (en) Methods of treating cold symptoms using pentoxifylline
CA2240717A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
EP0244083A3 (en) Amino acid derivatives
CA2139385A1 (en) Products containing g-csf and tnf binding protein
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
WO2000008007A3 (en) Cyclopentabenzofuran derivatives and their use
RO116771B1 (en) Method for preventing or treating the addiction on, tolerance or abuse of benzodiazepines
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA